Home > Products > By Targets > PD-L1 & TIGIT
PD-L1 & TIGIT Bispecific Antibodies
Product List Background

Product List

CAT# Product Name Species Reactivity BsAb Type Target 1 Host Animal 1 Target 2 Host Animal 2 INQUIRY
KN-0825-N53 Recombinant Human Anti-PD-L1 x Human Anti-TIGIT Bispecific Antibody (Fab-scFv-Fc) Human Fab-scFv/sdAb-Fc PD-L1 Human TIGIT Human Inquiry
KN-0825-N24 Recombinant Human Anti-PD-L1 x Human Anti-TIGIT Bispecific Antibody (IgG(H)-scFv) Human IgG-scFv PD-L1 Human TIGIT Human Inquiry
KN-0825-JL4 Anti-CD62L x Anti-PD-L1 Bispecific aptamer (DNA/DNA) Human Bispecific Aptamer CD62L PD-L1 Inquiry
KN-0825-N57 Recombinant Human Anti-PD-L1 x Human Anti-ICOS Bispecific Antibody (Fab-scFv-Fc) Human Fab-scFv/sdAb-Fc PD-L1 Human ICOS Human Inquiry
KN-0825-N38 Recombinant Human Anti-PD-L1 x Human Anti-4-1BB Bispecific Antibody (Fab-scFv-Fc) Human Fab-scFv/sdAb-Fc PD-L1 Human 4-1BB Human Inquiry
KN-0825-N28 Recombinant Human Anti-PD-L1 x Human Anti-ICOS Bispecific Antibody (IgG(H)-scFv) Human IgG-scFv PD-L1 Human ICOS Human Inquiry
KN-0825-N9 Recombinant Human Anti-PD-L1 x Human Anti-4-1BB Bispecific Antibody (IgG(H)-scFv) Human IgG-scFv PD-L1 Human 4-1BB Human Inquiry
KN-0825-N66 Recombinan Human Anti-PD-L1 x Human Anti-VISTA Bispecific Antibody (Fab-scFv-Fc) Human Fab-scFv/sdAb-Fc PD-L1 Human VISTA Human Inquiry
KN-0825-N65 Recombinan Human Anti-PD-L1 x Human Anti-CD3 Bispecific Antibody (Fab-scFv-Fc) Human Fab-scFv/sdAb-Fc PD-L1 Human CD3 Human Inquiry
KN-0825-N56 Recombinant Human Anti-PD-L1 x Human Anti-OX40 Bispecific Antibody (Fab-scFv-Fc) Human Fab-scFv/sdAb-Fc PD-L1 Human OX40 Human Inquiry
KN-0825-N55 Recombinant Human Anti-PD-L1 x Human Anti-CD27 Bispecific Antibody (Fab-scFv-Fc) Human Fab-scFv/sdAb-Fc PD-L1 Human CD27 Human Inquiry
KN-0825-N54 Recombinant Human Anti-PD-L1 x Human Anti-CD28 Bispecific Antibody (Fab-scFv-Fc) Human Fab-scFv/sdAb-Fc PD-L1 Human CD28 Human Inquiry
KN-0825-N52 Recombinant Human Anti-PD-L1 x Human Anti-CD47 Bispecific Antibody (Fab-scFv-Fc) Human Fab-scFv/sdAb-Fc PD-L1 Human CD47 Human Inquiry
KN-0825-N51 Recombinant Human Anti-PD-L1 x Human Anti-VEGF Bispecific Antibody (Fab-scFv-Fc) Human Fab-scFv/sdAb-Fc PD-L1 Human VEGF Human Inquiry
KN-0825-N50 Recombinant Human Anti-PD-L1 x Human Anti-TIM3 Bispecific Antibody (Fab-scFv-Fc) Human Fab-scFv/sdAb-Fc PD-L1 Human TIM3 Human Inquiry
KN-0825-N49 Recombinant Human Anti-PD-L1 x Human Anti-PD1 Bispecific Antibody (Fab-scFv-Fc) Human Fab-scFv/sdAb-Fc PD-L1 Human PD1 Human Inquiry
KN-0825-N48 Recombinant Human Anti-PD-L1 x Human Anti-LAG3 Bispecific Antibody (Fab-scFv-Fc) Human Fab-scFv/sdAb-Fc PD-L1 Human LAG3 Human Inquiry
KN-0825-N47 Recombinant Human Anti-PD-L1 x Human Anti-CTLA4 Bispecific Antibody (Fab-scFv-Fc) Human Fab-scFv/sdAb-Fc PD-L1 Human CTLA4 Human Inquiry
KN-0825-N46 Recombinant Human Anti-PD-L1 x Human Anti-EGFR Bispecific Antibody (Fab-scFv-Fc) Human Fab-scFv/sdAb-Fc PD-L1 Human EGFR Human Inquiry
KN-0825-N37 Recombinan Human Anti-PD-L1 x Human Anti-VISTA Bispecific Antibody (IgG(H)-scFv) Human IgG-scFv PD-L1 Human VISTA Human Inquiry
KN-0825-N36 Recombinan Human Anti-PD-L1 x Human Anti-CD3 Bispecific Antibody (IgG(H)-scFv) Human IgG-scFv PD-L1 Human CD3 Human Inquiry
KN-0825-N27 Recombinant Human Anti-PD-L1 x Human Anti-OX40 Bispecific Antibody (IgG(H)-scFv) Human IgG-scFv PD-L1 Human OX40 Human Inquiry
KN-0825-N26 Recombinant Human Anti-PD-L1 x Human Anti-CD27 Bispecific Antibody (IgG(H)-scFv) Human IgG-scFv PD-L1 Human CD27 Human Inquiry
KN-0825-N25 Recombinant Human Anti-PD-L1 x Human Anti-CD28 Bispecific Antibody (IgG(H)-scFv) Human IgG-scFv PD-L1 Human CD28 Human Inquiry
KN-0825-N23 Recombinant Human Anti-PD-L1 x Human Anti-CD47 Bispecific Antibody (IgG(H)-scFv) Human IgG-scFv PD-L1 Human CD47 Human Inquiry
KN-0825-N22 Recombinant Human Anti-PD-L1 x Human Anti-VEGF Bispecific Antibody (IgG(H)-scFv) Human IgG-scFv PD-L1 Human VEGF Human Inquiry
KN-0825-N21 Recombinant Human Anti-PD-L1 x Human Anti-TIM3 Bispecific Antibody (IgG(H)-scFv) Human IgG-scFv PD-L1 Human TIM3 Human Inquiry
KN-0825-N20 Recombinant Human Anti-PD-L1 x Human Anti-PD1 Bispecific Antibody (IgG(H)-scFv) Human IgG-scFv PD-L1 Human PD1 Human Inquiry
KN-0825-N19 Recombinant Human Anti-PD-L1 x Human Anti-LAG3 Bispecific Antibody (IgG(H)-scFv) Human IgG-scFv PD-L1 Human LAG3 Human Inquiry
KN-0825-N18 Recombinant Human Anti-PD-L1 x Human Anti-CTLA4 Bispecific Antibody (IgG(H)-scFv) Human IgG-scFv PD-L1 Human CTLA4 Human Inquiry
KN-0825-N17 Recombinant Human Anti-PD-L1 x Human Anti-EGFR Bispecific Antibody (IgG(H)-scFv) Human IgG-scFv PD-L1 Human EGFR Human Inquiry

Background

Programmed Death-Ligand 1 (PD-L1) is an immune checkpoint molecule expressed on antigen-presenting cells and various cancer cells, critically involved in modulating T-cell-mediated immune responses. Its interaction with programmed cell death protein 1 (PD-1) on activated T cells delivers inhibitory signals that suppress cytotoxic activity and promote immune tolerance-a mechanism exploited by malignancies to evade immune surveillance. Elevated PD-L1 expression has been documented across multiple tumor types including non-small cell lung carcinoma, melanoma, and gastrointestinal cancers, correlating with advanced disease progression and poorer prognostic outcomes.
TIGIT (T cell immunoglobulin and ITIM domain) is an emerging immune checkpoint receptor co-expressed on NK cells and T cells, functioning as a critical regulator of antitumor immunity. Structurally characterized by an immunoglobulin variable domain and an immunoreceptor tyrosine-based inhibitory motif (ITIM), TIGIT binds with high affinity to poliovirus receptor (PVR) ligands overexpressed on tumor cells, transmitting inhibitory signals that suppress cytotoxic lymphocyte activity through competitive disruption of DNAM-1-mediated activating signals. This mechanism parallels PD-1/PD-L1 pathway modulation but operates through distinct molecular interactions within the tumor microenvironment.
Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Welcome! For price inquiries, we will get back to you as soon as possible.

To order, please email

INQUIRY